FTC generics study
This article was originally published in The Tan Sheet
Executive Summary
FTC expects to complete its study of the impact of "authorized" generics in 2007. A March 29 release from the commission seeks comments on the study, which was requested by Sens. Charles Grassley (R-Iowa), Patrick Leahy (D-Vt.) and John Rockefeller (D-W.Va.) in May 2005. The senators sought to access the "short-term and long-term effects on competition" of authorized generics. The generics industry has been concerned that authorized generics discourage firms from challenging patents because it reduces the profit incentive of the 180-day exclusivity period. Proponents of the practice argue that having multiple generics on the market at that time reduces prices for consumers. Approximately 190 firms are expected to be surveyed. FTC will ask firms to report sales numbers and other figures for each affected product beginning a year before generic entry. FTC currently is seeking comments, however, on "ways to limit the number of companies included in the study without undermining the validity and reliability" of the results. Comments are due June 5...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.